Diabetes Drugs Market Size, Share and Industry Analysis By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Regional Forecast 2020 - 2029 (Includes COVID-19 Business Impact)

                                          
We have updated Diabetes Drugs Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Diabetes Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Diabetes Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Diabetes Drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Diabetes Drugs Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Diabetes Drugs Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
Novo Nordisk A/S
  
Sanofi
  
Merck & Co., Inc.
  
Eli Lilly and Company
  
AstraZeneca
  
Takeda Pharmaceutical Company Limited
  
Boehringer Ingelheim International GmbH
  
Novartis AG
  
Johnson & Johnson Services, Inc.
  
Bayer AG

Report Overview

Diabetes drugs are used for the treatment of diabetes mellitus. Insulin is safe as well as easier to administer and are more effective in maintaining the glucose level in patients with diabetes. The rapidly growing prevalence of diabetes and unmet demand in emerging nations are some of the factors anticipated to drive the diabetes drugs market growth by 2026.

The report provides qualitative and quantitative insights on the diabetes drugs industry and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented by drug class, by diabetes type, by route of administration, by distribution channel, and by region. On the basis of the drug class, the market is segmented into Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and others.

Diabetes type is segmented into type-1 and type-2 diabetes and the route of administration is segmented into oral, subcutaneous and intravenous. In the report, Online pharmacies, hospital pharmacies, and retail pharmacies are covered under the distribution channel segment. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the report provides elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of diabetes in key countries, introduction of new drugs/approvals by major key players, pipeline analysis, recent industry developments such as mergers, partnerships & acquisitions and the overview of regulatory scenario of key countries/regions.

SEGMENTATION

 SEGMENTATION

By Drug Class

  
Insulin
  
DPP-4 Inhibitors
  
GLP-1 Receptor Agonists
  
SGLT2 Inhibitors
  
Others

By Diabetes Type

  
Type 1
  
Type 2

By Route of Administration

  
Oral
  
Subcutaneous
  
Intravenous

By Distribution Channel

  
Online pharmacies
  
Hospital Pharmacies
  
Retail Pharmacies

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and Rest of Latin America)
  
Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Key Industry Developments

In April 2019, Glenmark launched its patent-protected novel anti-diabetic drug Remogliflozin in India. Remogliflozin is an SGLT2 inhibitor that will be used to treat type-2 diabetes mellitus in adults and will be commercialized under the brand names Remo and Remozen.

In May 2019, AstraZeneca received FDA approval to use Qternmet as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes.

In December 2016, Eli Lilly and Company received FDA approval to use Synjardy a combination of empagliflozin and metformin for the treatment of patients with type 2 diabetes.